Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arexvy
Pharma
GSK's Arexvy dominates RSV market ahead of new competition
The company's respiratory syncytial virus vaccine Arexvy takes some two-thirds of the RSV market share, GSK reported.
Zoey Becker
May 1, 2024 11:20am
Pfizer plots new RSV filing with positive Abrysvo data in adults
Apr 9, 2024 6:45am
GSK boosts CEO Emma Walmsley's pay to £12.7M after strong year
Mar 5, 2024 2:39pm
Pfizer, GSK RSV shots may raise Guillain-Barré risk: officials
Mar 4, 2024 11:46am
In year 2, Pfizer's RSV vax Abrysvo retains most of its efficacy
Feb 29, 2024 8:02am
Analysts tip label expansion to bolster GSK's hand in RSV fight
Feb 7, 2024 7:20am